Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name Ujvira. HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25% of all Breast Cancers.
- Read more about Zydus launches Ujvira (Trastuzumab Emtansine), a breakthrough in Breast Cancer treatment
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/zydus-launches-ujvira-trastuzumab-emtansine-a-breakthrough-in-breast-cancer-treatment
No comments:
Post a Comment